PRPF19 promotes tongue cancer growth and chemoradiotherapy resistance. (6th May 2021)

• Record Type: Journal Article
• Authors: He, Yihong; Huang, Changhao; Cai, Kaimei; Liu, Pei; Chen, Xueyan; Xu, Y i; Ming, Zhengnan; Liu, Qingqing; Xie, Qiongxuan; Xia, Xue; Sun, Yangqing; Luo, Junli; Wei, Rui
• Is Part Of: Acta biochimica et biophysica Sinica. Volume 53:Number 7(2021)
• Page Start: 893
• Page End: 902
• Publication Date: 2021-05-06
• Subjects: PRPF19 -- tongue cancer -- chemoradiotherapy resistance -- recurrence; Biochemistry -- Periodicals; Biophysics -- Periodicals; 572.05
• DOI: 10.1093/abbs/gmab059
• Languages: English
• ISSNs: 1672-9145

Abstract

Abstract: Pre-mRNA processing factor 19 (PRPF19) is a multifaceted protein and participates in DNA damage response and pre-mRNA processing. The role of PRPF19 in cancer is unclear. Here, we report that the expression of PRPF19 in human tongue cancer is associated with unfavorable prognosis. Overexpression of PRPF19 promotes while knockdown of PRPF19 inhibits tongue cancer cell migration, proliferation, and tumor growth. Overexpression of PRPF19 increases the resistance of tongue cancer cells to radiation and cisplatin treatment. Furthermore, PRPF19 regulates the expression of solute carrier family 40 member 1 (SLC40A1) and mono-ADP ribosylhydrolase 2 (MACROD2), knockdown of SLC40A1 or MACROD2 decreases the sensitivity of tongue cancer cells to radiation and cisplatin treatment. Thus, our results establish a key role of PRPF19 in tongue cancer growth and chemoradiotherapy resistance, targeting PRPF19 would be an effective therapeutic strategy for tongue cancer, especially for those resistant to chemoradiotherapy.